European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 96

Vaccines Communication Immunity Immunization 96

Pharmafile

SEPTEMBER 28, 2023

The University of Birmingham hosted Bacterial Vaccines Network has been awarded £1.4m in funding from the UK government to accelerate the development of bacterial vaccines in the fight against antimicrobial resistance (AMR). This funding follows the Global AMR Innovation Fund’s (GAMRIF) £1.4m

Vaccines 59

Vaccines 59

European Pharmaceutical Review

AUGUST 24, 2023

GSK’s Shingrix (Recombinant Zoster Vaccine or RZV) vaccine has been shown to offer 100 percent efficacy against shingles in adults 50 years old and over in China. The Phase IV trial (ZOSTER-076) is the first-ever efficacy trial of the shingles vaccine Shingrix in China. Shingrix is a non-live, recombinant subunit vaccine.

Vaccines 92

Vaccines 92

European Pharmaceutical Review

SEPTEMBER 28, 2023

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

Vaccines 79

Vaccines Pharmaceutical Manufacturing 79

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 79

Vaccines Immunity Immunization Documentation 79

pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. The post BioNTech takes its first cancer vaccine into phase 2 appeared first on.

Vaccines 145

Vaccines Immunity Immunization 145

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccines 78

Vaccines Immunity Immunization 78

pharmaphorum

JULY 21, 2022

GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial virus (RSV) infections. ” The post Ex-GSK vaccine chief to lead new UK biotech Vicebio appeared first on. . ” He said.

Vaccines 105

Vaccines Immunity Immunization 105

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

AUGUST 22, 2022

UNICEF has awarded GSK the first ever contract for the supply of a malaria vaccine. This vaccine rollout gives a clear message to malaria vaccine developers to continue their work because malaria vaccines are needed and wanted,” commented Etleva Kadilli, Director of UNICEF’s Supply Division. “We

Vaccines 92

Vaccines 92

Pharmaceutical Business Review

JULY 21, 2023

Earlier known as AV7909, CYFENDUS vaccine’s efficacy for post-exposure prophylaxis is only based on studies in animal models of inhalational anthrax. Emergent senior vice president, science and development Dr. Kelly Warfield said: “The approval of CYFENDUS vaccine is symbolic of Emergent’s longstanding partnership with the U.S.

Vaccines 52

Vaccines Immunity Immunization Packaging 52

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccines 97

Vaccines Immunity Immunization 97

pharmaphorum

NOVEMBER 29, 2021

The UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – is rumoured to be up for sale. It was billed at the time as a key tool to accelerate the development of new and innovative vaccines to combat some of the world’s most prevalent diseases, from discovery to licensed product.

Vaccines 105

Vaccines 105

pharmaphorum

JULY 27, 2021

Flushed with the success of its COVID-19 vaccine, BioNTech has pressed the accelerator on the development of shots for other infectious diseases, and now plans to take malaria and tuberculosis candidates into the clinic next year. The post BioNTech’s mRNA vaccine drive now includes malaria, TB shots appeared first on.

Vaccines 106

Vaccines 106

NY Times

MAY 5, 2021

pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines. The Biden administration, siding with some world leaders over the U.S.

Vaccines 140

Vaccines Immunity Immunization 140

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108

Vaccines Drug Pricing Biosimilars Documentation 108

NY Times

DECEMBER 11, 2020

British health officials recommended that people with severe allergy reactions not be given the vaccine. Such reactions to vaccines are rare, even in people who have allergies to food or bee stings.

Vaccines 140

Vaccines Immunity Immunization 140

Pharmacy Times

NOVEMBER 16, 2022

In a 2019 survey, middle-aged participants were considerably more apprehensive about getting vaccinated than younger groups, which was not the case in the 2022 survey.

Vaccines 52

Vaccines 52

NY Times

AUGUST 20, 2021

Federal regulators are winding down the process of licensing Pfizer’s two-dose coronavirus vaccine, setting up an approval possibly by Monday and possibly kicking off a wave of new mandates.

Vaccines 145

Vaccines Immunity Immunization 145

NY Times

FEBRUARY 8, 2022

A crucial Johnson & Johnson plant has stopped making its Covid vaccine, though the company says it has millions of doses in inventory.

Vaccines 143

Vaccines Immunity Immunization 143

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Spikevax is an mRNA vaccine that is approved in 20 geographies including the US, EU, and, the UK. The vaccine first gained Emergency Use Approval in December 2020 in response to the Covid-19 pandemic.

Vaccines 59

Vaccines 59

PharmExec

MARCH 13, 2024

Data shows that from 2014-2019, pneumococcal vaccinations in seniors increased by 10%, growing sales for Prevnar 13 due to government recommendation in addition to a high-profile advertising campaign.

Vaccines 52

Vaccines 52

NY Times

JANUARY 26, 2021

President Biden said the amount of coronavirus vaccines reaching the states would rise next week and a deal was near to provide enough shots to vaccinate nearly all Americans by the end of summer.

Vaccines 124

Vaccines Immunity Immunization 124

NY Times

JUNE 13, 2022

Outside experts will make their recommendations this week on how the agency should rule on applications from Pfizer and Moderna to vaccinate the nation’s youngest children.

Vaccines 105

Vaccines Immunity Immunization 105

NY Times

DECEMBER 25, 2020

Until now, reports of severe reactions had been linked to the Pfizer vaccine. The patient, who has a severe shellfish allergy, recovered quickly with treatment.

Vaccines 145

Vaccines Immunity Immunization 145

NY Times

OCTOBER 9, 2021

Some poorer countries are paying more and waiting longer for the company’s vaccine than the wealthy — if they have access at all.

Vaccines 145

Vaccines Immunity Immunization 145

NY Times

DECEMBER 18, 2020

The Food and Drug Administration authorized a second coronavirus vaccine for emergency use, clearing the way for millions more Americans to be immunized next week.

Vaccines 105

Vaccines Immunity Immunization Nursing Homes 105

NY Times

AUGUST 3, 2021

The Food and Drug Administration’s move is expected to kick off more vaccination mandates for hospital workers, college students and federal troops.

Vaccines 145

Vaccines Hospitals Immunity Immunization 145

Pharma Mirror

SEPTEMBER 22, 2021

Nantes, France, Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors, today announces the next phase in its partnership with FluGen, Inc., The company’s.

Vaccines 52

Vaccines 52

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.

Vaccines 246

Vaccines Bioethics Immunity Immunization 246

NY Times

OCTOBER 21, 2021

The company said that in a study, boosters cut down the number of breakthrough infections among fully vaccinated people by more than 95 percent.

Vaccines 145

Vaccines Immunity Immunization 145

Pharmaceutical Technology

JANUARY 30, 2023

According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. Of these 22 vaccines, mRNA-derived vaccines dominate, with Comirnaty and Moderna’s Spikvax accounting for 88% of 2022 sales, with 58% and 30%, respectively.

Vaccines 52

Vaccines 52

NY Times

MARCH 4, 2021

Johnson & Johnson’s one-shot vaccine is allowing states to rethink distribution, even as health officials and experts worry some will view it as inferior.

Vaccines 134

Vaccines Immunity Immunization 134

pharmaphorum

SEPTEMBER 8, 2022

On the strength of phase 2 data, the FDA has awarded coveted breakthrough status to Pfizer’s vaccine against Group B Streptococcus (GBS), given to expectant mothers to prevent invasive infections in newborns and young infants. The post FDA gives Pfizer’s Group B strep vaccine breakthrough status appeared first on.

Vaccines 52

Vaccines 52

NY Times

AUGUST 23, 2021

The move was expected to kick off a round of new vaccination mandates from hospitals, schools and private companies.

Vaccines 98

Vaccines Hospitals Immunity Immunization 98

Pharmacy Times

JUNE 27, 2022

The FDA approved the first vaccine for dengue disease in May 2019.

Vaccines 54

Vaccines 54

pharmaphorum

MAY 30, 2022

Shares in Swedish biotech RhoVac were down 94% in mid-morning trading today after the company revealed a phase 2b trial of its prostate cancer vaccine RV001 showed it was no more effective than placebo. The post RhoVac pummelled as lead cancer vaccine fails study appeared first on.

Vaccines 72

Vaccines 72